^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CSF2 elevation

i
Other names: CSF2, GM-CSF, GMCSF, Colony stimulating factor 2 (granulocyte-macrophage)
Entrez ID:
Related biomarkers:
1year
Increased response to granulocyte-macrophage colony-stimulating factor in peripheral blood cells and transient manifestations mimicking juvenile myelomonocytic leukemia in a male patient with NEMO deficiency caused by a deep intronic pathogenic variant of IKBKG. (PubMed, Immunol Med)
The patient with NEMO deficiency demonstrated JMML-like manifestation and severe inflammation. PBMCs of the patient demonstrated increased RAS signaling activation with unknown pathophysiology.
Journal
|
CSF2 (Colony stimulating factor 2)
|
CSF2 elevation
1year
Increased CD14+HLA-DR-/low myeloid-derived suppressor cells can be regarded as a biomarker on disease severity and response to therapy in acute coronary syndrome. (PubMed, PeerJ)
Assessment of M-MDSCs frequency holds promise as a predictive marker for disease progression and therapy response of coronary artery stenosis. The elevated presence of M-MDSCs suggests their potential role in modulating ACS-related inflammation.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • CSF2 (Colony stimulating factor 2) • ARG1 (Arginase 1)
|
CSF2 expression • CSF2 elevation • IL6 expression
1year
Garlic Bioconverted by Bacillus subtilis Stimulates the Intestinal Immune System and Modulates Gut Microbiota Composition. (PubMed, Mol Nutr Food Res)
This study provides the first evidence of BGF's ability to modulate the intestinal immune system and gut microbiota, supporting its potential as a novel functional material to enhance gut immunity.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
CSF2 elevation
over1year
Protection of neutrophils by bone marrow mesenchymal stromal cells is enhanced by tumor-associated inflammatory cytokines. (PubMed, Front Immunol)
Furthermore, we found that IFNγ and TNFα-treated MSCs enhanced their capability of promoting neutrophil survival and maturation. Our results indicate that MSCs display robustly protective effects on neutrophils to contribute to tumor growth in bone niches.
Journal • Stroma
|
IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2)
|
CSF2 elevation
over1year
Lipopolysaccharide regulation of antiinflammatory tristetraprolin family and proinflammatory gene expression in mouse macrophages. (PubMed, BMC Res Notes)
LPS increased mRNA levels of TNF, COX2, GM-CSF, INFγ and IL12b up to 311, 418, 11, 9 and 4 fold, respectively. This study demonstrated that LPS did not affect macrophage viability, dramatically increased antiinflammatory TTP gene expression as well as proinflammatory TNF and COX2 gene expression but had only mild effects on TTP homologues and other proinflammatory cytokine gene expression in the mouse macrophages.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CSF2 (Colony stimulating factor 2) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • ZFP36 (ZFP36 Ring Finger Protein)
|
CSF2 elevation
almost2years
EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth. (PubMed, Cancer Discov)
Alternate strategies harnessing anticancer innate immunity are required for lung cancers with poor response rates to T cell-based immunotherapies. This study identifies a targetable, mutually supportive, metabolic relationship between macrophages and transformed epithelium, which is exploited by tumors to obtain metabolic and immunologic support to sustain proliferation and oncogenic signaling.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
EGFR mutation • CSF2 elevation
almost2years
EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth. (PubMed, Cancer Discov)
In the absence of TA-AM metabolic support, LUAD cells compensate by increasing cholesterol synthesis, and blocking PPARγ in TA-AMs simultaneous with statin therapy further suppresses tumor progression and increases proinflammatory immune responses. These results reveal new therapeutic combinations for immunotherapy resistant EGFR-mutant LUADs and demonstrate how cancer cells can metabolically co-opt TA-AMs through GM-CSF-PPARγ signaling to provide nutrients that promote oncogenic signaling and growth.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
EGFR mutation • CSF2 elevation
almost2years
Transcription Factor E2F7 Hampers the Killing Effect of NK Cells against Colorectal Cancer Cells via Activating RAD18 Transcription. (PubMed, J Microbiol Biotechnol)
E2F7 could activate the transcription of RAD18, and silencing RAD18 reversed the inhibitory effect of E2F7 overexpression on NK cell killing. This work clarified the inhibitory effect of the E2F7/RAD18 axis on NK cell killing in CRC, and proffered a new direction for immunotherapy of CRC in targeted immune microenvironment.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • PRF1 (Perforin 1) • E2F7 (E2F Transcription Factor 7) • TCF7 (Transcription Factor 7) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
IFNG expression • CSF2 elevation
2years
Preclinical • Journal • IO biomarker
|
CASP3 (Caspase 3) • CSF2 (Colony stimulating factor 2) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
|
CSF2 expression • CSF2 elevation • IFNA1 expression
2years
Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling (ASH 2023)
Targeting this axis diminished the neurotoxicity associated with this therapy. This study provides a rationale for testing TAK1-inhibition in a clinical trial for treating CD19 CAR-T cell-induced neurotoxicity.
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
|
CSF2 expression • CSF2 elevation